Patients don’t take their medication, but you don’t often know why, or when they stopped.
Patients might stop taking their medication for a variety of reasons: medications can be effective and patients think they can take a treatment “vacation”, patients could run into avoidable side effects, or comorbid conditions may hamper treatment.
Mere reminders don’t work—they don’t address root drivers of non-adherence.
Understanding Your Patients
Interacting with your patients on a daily basis is not cost-effective.
However, having more frequent touch points would improve your understanding for your patients and their challenges.
Promoting Your Medical Solutions
New biopharmaceutical drugs are extremely effective at combating diseases, but justifying their use can be difficult without having real-world data about how they improve a patient’s quality of life. This information can be provided by Mabu
WE CAN HELP
Mabu has daily two to three minute conversations with patients to check in not only on whether they’re taking their medication, but also on what challenges a patient is facing, diving into why a medication regimen is working for a patient, or why it’s not.
Because the core artificial intelligence behind Mabu’s interactions with the patient center on relationship building, and because Mabu is physically present, Mabu builds and deepens long-term engagement.
Because patients continue to interact with Mabu, she can continue to help them with their care management, dosage, and education, and track disease progression to anticipate challenges a patient might face even before they occur.
Daily interactions provide granular data that can give insights into patients, draw commonalities between patient populations, and help you continuously improve your care management.
Mabu can provide data that shows how patients quality of life improves. This information can be invaluable, both for showing providers and payers to convince them not just about the efficacy of your drug, but the ways in which it improves patients lives in the real world.